Avadel Pharmaceuticals PLC (STU:AWK)
€ 10 0.15 (1.52%) Market Cap: 949.15 Mil Enterprise Value: 888.38 Mil PE Ratio: 0 PB Ratio: 13.69 GF Score: 42/100

Avadel Pharmaceuticals PLC at Stifel CNS Days (Virtual) Transcript

Mar 29, 2022 / 04:00PM GMT
Release Date Price: €6.05 (-2.42%)
Paul Matteis
Stifel Financial Corp. - Analyst

Great. Thanks very much and good afternoon, everybody. Appreciate you continuing on to listen in here. It's my pleasure to be moderating the panel with Greg Divis, CEO of Avadel. Greg, it's always fun. Maybe you could kick things off with some opening remarks and just say what you can say about the ongoing FT218 review and your launch prep, and then we can get into specifics. So thanks again.

Greg Divis
Avadel Pharmaceuticals PLC - CEO

Yeah. First of all, Paul, thanks. We always appreciate the opportunity to participate in these chats with you and talk to some of your clients. So maybe I'll just frame things up a little bit and provide a little bit of background as well to set the stage. Just as a reminder for folks, we originally had a target PDUFA date of October 15. We were notified that just at that time that the FDA needed more time to complete the review, but they didn't have any questions for us at that point in time.

Clearly, the review progressed through the balance of last year and more work

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot